Marshall on Oncology

• Waves of Emotion, Understanding After PBS Cancer   Dr John Marshall asks clinicians to be mindful of the emotional response cancer patients will have to the PBS Cancer documentary--and to use heightened public awareness to push for research funding.
  Medscape Oncology, March 30, 2015
• Is 'Conflict of Interest' Hampering Cancer Research?   Dr John Marshall discusses how the current requirements for declaring conflict of interest are complicating cancer research and possibly barring the best minds from working together.
  Medscape Oncology, March 09, 2015
• Coverage Cut-off for Cancer Costs?   Will US and European guidelines follow the UK's lead and incorporate value metrics in their recommendations? Dr. John Marshall, reporting on a discussion at GICS, says it's only a matter of time.
  Medscape Oncology, February 18, 2015
• Immuno Death Ray to GI Cancers   Can immunotherapy 'clip the force field' of gastrointestinal tumors? Dr John Marshall and experts say yes and will discuss advances during the Ruesch Symposium 2014, December 5, Washington, DC.
  Medscape Oncology, November 25, 2014
• Longer Life, at Any Cost?   Dr John Marshall asks his cancer patients on their first visit: How long do you want to live? Their answers have implications for the practice of oncology -- and the healthcare system as a whole.
  Medscape Oncology, October 30, 2014
• Cologuard: Breakthrough in CRC Screening   Dr. John Marshall discusses Cologuard, a new screening test for colorectal cancer that can detect CRC missed by colonoscopy, which he hopes will keep masses of patients out of his office.
  Medscape Oncology, September 05, 2014
• Why Don't CRC Survival Data Add Up?   Dr. John Marshall questions why the survival rate in a large phase 3 trial presented at ASCO was nearly double the survival rates achieved by earlier trials while using the same medicines.
  Medscape Oncology, August 04, 2014
• Dad's Gifts: From Go-Karts to Joy Rides   Dr. John Marshall's father taught him how to fix things, and in the process, set for him an example of joy that fixed him for life.
  Medscape Oncology, June 13, 2014
• GI Cancer's 'Paparazzi Moment'   Dr. John Marshall says GI cancer's paparazzi moment at ASCO will be the plenary session spotlighting a head-to-head comparison of one biologic class against another in first-line colon disease.
  Medscape Oncology, May 23, 2014
• Silence the Mouse Model That Roared   Dr. John Marshall says that generous funding of basic science is an inefficient and misdirected use of cancer research dollars. The focus needs to be on innovative, clinical translational research.
  Medscape Oncology, April 16, 2014
• Resected Pancreatic Cancer: Why Wait for the Inevitable?   Dr. John Marshall reports on a retrospective study suggesting that maintenance with capecitabine is a promising option in patients with resected pancreatic adenocarcinoma after adjuvant therapy.
  Medscape Oncology, April 04, 2014
• Is Adjuvant Chemo Needed in Rectal Cancer?   Dr. John Marshall asks, 'Why are we giving patients oxaliplatin when our evidence doesn't demonstrate much, if any, benefit?
  Medscape Oncology, April 03, 2014
• Taking the Boards: A Frisking, Then a Mugging   Dr. John Marshall found board certification 'really hard,' partly because questions had no right answer. He asks: Are boards a fair measure of a practicing physician's skills and knowledge base?
  Medscape Oncology, March 20, 2014
• Caution! Anti-EGFR Therapy May Endanger mCRC Patients   Dr. John Marshall reports that in patients with metastatic colorectal cancer, anti-EGFR therapy could not only prove ineffective but actually harmful, depending on their RAS mutations.
  Medscape Oncology, February 24, 2014
• Dazed and Confused About Molecular Data?   Is molecular profiling integral to choice of treatment or simply a source of confusion? Dr. John Marshall speaks to issues that need to be resolved before 'personalized medicine' is practice-ready.
  Medscape Oncology, October 23, 2013
• Who's in It for the Cure?   Dr. John Marshall takes to his electronic chalkboard to tackle the problem of coordinating the separate agendas of cancer stakeholders, and finds a simple yet elegant solution.
  Medscape Oncology, August 19, 2013
• A C-change in Adjuvant Pancreas Cancer?   Dr. John Marshall reports on progress in treatment of metastatic pancreas cancer using traditional drugs, and questions current use of adjuvant capecitabine on the basis of a recent study from Japan.
  Medscape Oncology, August 05, 2013
• Least Is Best in CRC Follow-up   Drs. David Kerr and John Marshall discuss colorectal cancer highlights from ASCO, including findings on follow-up scans, chemo holidays, and drug combos.
  Medscape Oncology, June 13, 2013
• 'GI Gang' Goes in for Refinements   Dr. John Marshall previews important topics to be addressed in the GI poster sessions at ASCO, including front-line and maintenance therapies for CRC, and adds a personal wish.
  Medscape Oncology, May 23, 2013
• Get a Dog and Start Walking   Modest exercise can improve survival in patients with colorectal cancer at a rate superior to that for adjuvant therapy, says Dr. John Marshall. Time to tell patients to lace up their sneakers.
  Medscape Oncology, March 15, 2013